Quantum Cyber N.V. Rightofuse Assets Revalued Assets At Cost
Quantum Cyber N.V. (QUCY) had Rightofuse Assets Revalued Assets At Cost of $2.39 million as of 2025-06-30, per its 6-K filed 2025-09-26.
Financial Statements › Notes
ifrs-full:RightofuseAssetsRevaluedAssetsAtCost · last filed 2025-09-26
- 2025-06-30: Rightofuse Assets Revalued Assets At Cost $2.39M.
- 2024-12-31: Rightofuse Assets Revalued Assets At Cost $1.89M.
- 2024-06-30: Rightofuse Assets Revalued Assets At Cost $2.00M.
- 2023-12-31: Rightofuse Assets Revalued Assets At Cost $1.96M.
| Period end | Rightofuse Assets Revalued Assets At Cost |
|---|---|
| 2025-06-30 | $2.39M 6-K · filed 2025-09-26 |
| 2024-12-31 | $1.89M 6-K · filed 2025-09-26 |
| 2024-06-30 | $2.00M 6-K · filed 2024-10-18 |
| 2023-12-31 | $1.96M 20-F · filed 2025-03-31 |
| 2022-12-31 | $1.56M 20-F · filed 2025-03-31 |
| 2021-12-31 | $559.97K 20-F · filed 2024-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |